cally relevant parameters for efficacy (response and remission rates) and tolerability (discontinuation rates and discontinuation due to adverse effects), and we will estimate effect sizes for various doses with the aim of detecting a possible dose-dependent effect. Further, we compare desvenlafaxine with other antidepressant agents, if any head-to-head trials are available.
Introduction ▼
Desvenlafaxine is a relatively novel agent that was approved in 2008 in the USA for the treatment of major depressive disorder. It is the main metabolite of venlafaxine, a selective serotonin and norepinephrine reuptake inhibitor, which is considered to be one of the most effective antidepressants today [1] . Desvenlafaxine appears to share the same pharmacodynamic properties as the parent substance [2] . The efficacy of active metabolites is not self-evident and should not be taken for granted; for example, the active metabolite of clozapine -the most effective antipsychotic drug [3] -was not found to be effective in the treatment of schizophrenia. Several trials have been conducted so far on the efficacy of desvenlafaxine in the treatment of major depressive disorder and an early meta-analysis showed significant results in both primary (HAM-D 17 scores) and secondary (response and remission rates) outcomes [4] . The efficacy of desvenlafaxine has been tested further in more recent studies, thus making it imperative to update the first review. The objective of our review is to give an overview of the existing literature; we focus solely on clini-
Article selection and review strategy
The selection of studies involved an initial screening of title and abstract in order to find studies fulfilling the above inclusion criteria. If it was not clear from the title or abstract that a study should be rejected, the full text was obtained. This process was conducted independently by both authors in order to reduce the possibility of rejecting relevant articles. The data were extracted independently by both authors. In case of disagreement, a clinician experienced in psychopharmacology could be consulted to mediate consensual decisions. Dichotomous data (rates for response and remission) were collected for the primary outcomes of this review. Secondary outcomes were the risk of dropouts due to any reason and the risk of dropouts due to adverse effects.
Statistical methods (meta-analysis)
Meta-analysis was performed when more than one trial was available in either group of studies (placebo-controlled and head-to-head trials). A random-effects model was applied because of the assumption that the true effect size was not the same in all studies. Relative risk ratios (RR) were computed for dichotomous data, because they have the advantage of being more intuitive than odds ratios (OR). A significant proportion of meta-analyses use the odds ratio as the main effect size; in order to make our results comparable with the results from other studies we also estimated the OR for response, remission and discontinuation. Values for RR and OR greater than 1 mean that desvenlafaxine is superior over placebo or the compared antidepressant (and vice versa for values under 1). In estimating risk ratios for response and remission, we accepted the recommendation of the Cochrane Handbook for systematic reviews, that if data from the intention-to-treat population are not reported, an available case analysis is the best alternative [5] . In the case of unusable data (e. g., analysis per protocol) the study was excluded at first from our main analysis and sensitivity analysis was performed afterwards in order to evaluate the impact of the trial on the overall effect size. In the case of zero events trials (in one or in both arms), the standard continuity correction of 0.5 was applied [6] . If data were not provided in the article or were reported in a non-useful way, the corresponding authors were contacted. When this approach was unfruitful, we proceeded as follows: a) we searched in previous reviews and reports for suitable data, b) when data were reported as proportions, we converted them back to natural numbers. If the result was unclear, the mean of the possible values was used in the main analysis (for example, if a group of 150 patients is reported to have 65 % responders, the possible number of responders is 97 or 98, in which case 97.5 was used in the main analysis). In order to ensure that this method did not have a significant impact on the results, we performed sensitivity analysis (first sensitivity analysis or SA-1) for the best case (highest number of the verum group and lowest number of the placebo group) and the worst case (exactly the opposite) scenario. c) We extracted data from graphs using the WebPlotDigitizer Version 3.3 [Ankit Rohatgi (2014), ZENODO, 10.5281/zenodo.10532]. d) If graphs were not available, we converted continuous data to dichotomous by the method described by Furukawa et al. [7] . This method is applicable only for response rates, not for remission rates. The calculations were performed using standard formulas in Microsoft Excel (Excel 2003 Edition, Microsoft, Redmond, WA) [8] . The forest plot was also created in Microsoft Excel according to a guide published by Neyeloff et al. [9] . Heterogeneity I 2 was computed in order to assess the percentage of the overall variability attributed to between-study variability. The risk of bias in individual studies was evaluated using the Cochrane Collaboration's domain-based tool, which assesses allocation concealment, sequence generation, blinding, selective outcome reporting and other sources of bias. The risk of publication bias was assessed using a funnel plot and Egger's regression method [10] .
Results

▼
Search results
The electronic searches provided 326 references from MEDLINE, 935 from EMBASE and 95 references (clinical trials) from the Cochrane Library. After the initial scanning of the abstracts a total of 20 reports remained. These reports were further screened and assessed for eligibility and 5 of them were rejected. The remaining 14 reports fulfilled the inclusion criteria for the review (see flow diagram in • ▶ Fig. 1 ). Details for each trial are presented in • ▶ Table 1 . The complete list of the assessed trials and the reasons for rejection appear in Appendix A. 11 reports with a total of 12 placebo-controlled trials qualified for our main analysis [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . 2 of these were 3-arm studies which included a group that received a dose of desvenlafaxine below 50 mg; these 2 groups were excluded from the main analysis and included in an additional sensitivity analysis (second sensitivity analysis or SA-2), since in daily practice desvenlafaxine is not used in a dose of 10 mg or 25 mg. In addition, we found in 2 reviews an unpublished report with the code name Des 223, which was also included in the main analysis. 3 further placebocontrolled RCTs were identified [22] [23] [24] : 2 of them included only perimenopausal and postmenopausal women, while the third included only patients who were employed. These 3 last trials used a slightly different design: They recruited patients based on their MADRS score (a cutoff of 22 or 25), but estimated the response rates based on HAM-D scores in a subpopulation of the original sample, which had an initial HAM-D score above 18. Because of the different populations and study design, these 3 articles were used only in sensitivity analyses (third sensitivity analysis or SA-3). The exact numbers of responders in trials that were published before 2009 were provided in the official withdrawal assessment report of the European Medicine Agency. In the other cases, the reported proportions were used to estimate the number of responders as described in the methods section. In 2 cases the remission rates were not reported [11, 16] ; we extracted the data from the provided graphs using WebPlotDesigner. A separate meta-analysis was performed with 4 head-to-head trials, which enabled a direct comparison of the efficacy of desvenlafaxine and other antidepressants. 2 of the above-mentioned reports (with a total of 3 trials) included an additional comparison group that received another antidepressant (venlafaxine in 2 cases and duloxetine in the third case) [15, 18] . The third report included no placebo group and compared desvenlafaxine with escitalopram in peri-and postmenopausal women with depression [25] .
Meta-analysis Effect size for efficacy
In the main analysis the mean risk ratio for response was 1.24
(95 % CI: 1.16-1.32; p < 0.001) ( • ▶ Fig. 2 ) and the mean risk ratio 
Efficacy of fixed doses and comparisons between them
We estimated the risk ratios for response and remission for 4 separate doses ( • ▶ Head-to-head trials 3 comparisons in total were possible: desvenlafaxine against venlafaxine, against SSNRIs (i. e., venlafaxine and duloxetine), and against antidepressants in general (i. e., venlafaxine, duloxetine and escitalopram). The risk ratios for response and remission were statistically significant only in the third comparison in favor of the other antidepressants. All results are presented in • ▶ Table 6 .
Heterogeneity
The computed heterogeneity I² was 0 % in the main analysis for response (95 % CI: 0-34 %) and 0 % in the main analysis for remission rates (95 % CI: 0-29 %). In our sensitivity analyses the heterogeneity remained low. Here, the low heterogeneity can be attributed to the similar designs of the studies included in the analysis and the homogeneity of the studied population.
First Author
Year Number of remitters were extracted from graphs 3 Number of responders and remitters were calculated from ratios provided in the articles 4 Number of responders and remitters were extracted from data published in ClinicalTrials.gov Table 1 Continued.
Risk of bias and publication bias
The risk of bias for each study can be determined by assessing the following 6 domains: (1) sequence generation, (2) allocation concealment, (3) blinding, (4) missing data, (5) selective outcome reporting, and (6) other sources of bias. The overall risk of bias could be described as moderate ( • ▶ Fig. 3) . The results for the individual trials are presented in Appendix B. Finally, there is no indication of publication bias after visual inspection of the funnel plot; in particular, there is no gap on the bottom left side, which would be indicative of unpublished studies with small to moderate effects ( • ▶ Fig. 4 ). Egger's regression method also gave no indication of publication bias, since the intercept of the fitted line was near zero ( • ▶ Fig. 5 ).
Discussion
▼
Results
The mean risk ratio for response was found to be 1.24 (95 % CI: 1.16-1.32; p < 0.001), i. e., a therapeutic response is 25 % more likely with the use of desvenlafaxine than in the placebo group, which can be regarded at best as a very moderate effect. Considering the fact that venlafaxine is currently one of the most effective antidepressants, this finding was quite unexpected. The head-to-head comparisons also provide some evidence that desvenlafaxine may be inferior when compared with other antidepressants. However, the robustness of these results is limited by the small number of included trials (only 4) and the heterogeneity of the population studied (one study included only peri-and postmenopausal women with depression). Further trials with direct comparisons are necessary in order to draw definite conclusions.
In our analysis there were no significant differences in the risk ratios for response and remission between the various doses (i. e., 50 mg, 100 mg, 200 mg and 400 mg), although the 2 higher doses tended to have higher response rates. The lowest rates were found for the 50 mg dose and the highest rates for the 200 mg dose. . In all, duloxetine and especially venlafaxine seem to have a better efficacy than desvenlafaxine, while tolerability of all 3 agents seems to be similar. The above discrepancy in the odds ratios may reflect a true difference in the efficacies of desvenlafaxine and the other 2 SSN-RIs, or alternatively can be attributed to factors related to the study design of the trials; for example multi-site and multi-arm trials can lead to an increased placebo effect; all desvenlafaxine trials were multi-site and 10 of the 12 studies in the main analysis were multi-arm [27, 28] . It has also been mentioned that in more recent studies a higher placebo effect has been noticed in comparison to older ones [27] . Since desvenlafaxine is the newest drug of the 3, this factor might also have played a role.
A recent meta-analysis performed an indirect comparison between desvenlafaxine and its parent substance and found no differences in their efficacy [29] . However, this study included only 7 trials with desvenlafaxine with a total of 2 380 patients, about half the number included in our analysis. The authors did not report the risk ratios separately for each drug; when repeating our analysis using the population included in this indirect comparison, we found a risk ratio for response of 1.29 (95 % CI: 1.18-1.42, p < 0.001) for desvenlafaxine, which is quite similar to our results. A non-significant difference between the 2 agents implies a similarly low efficacy for venlafaxine, which contradicts the results of the above meta-analysis by Schueler et al. In order to compare the results of all 3 studies, we estimated additionally the risk ratio for response to venlafaxine using the data provided in this latter meta-analysis; the results are presented in • ▶ Table 7 . The confidence intervals of the risk ratios for venlafaxine overlap those for desvenlafaxine, as estimated both in the study by Coleman et al. and in our study. However, the odds ratios for response in our study in contrast to that by Coleman et al. appear to be significantly lower than the odds ratio for response for venlafaxine. Although this comparison is equivocal, it clearly demonstrates that it has not yet been established that the 2 agents are equally effective.
Marketing active metabolites
As mentioned above, the efficacy of active metabolites cannot be taken for granted. For example, norclozapine (desmethylclozapine or ACP-104) was ineffective in phase 2 trials in the treatment of schizophrenia, and further trials were not performed [30] . Similarly, the S-enantiomer of norfluoxetine (seproxetine), which is the main active metabolite of fluoxetine, did not qualify for phase 3 trials [31] . Leucht et al. showed in a recent metaanalysis that risperidone did not differ in either efficacy or safety parameters from its active metabolite paliperidone [3] . Consid-ering the fact that the active metabolites are much more expensive than the parent substances, whose patents have already expired, superiority or at least an equivalence of the former over the latter in terms of efficacy and tolerability should be demanded in order to justify their use.
Limitations and strengths
One limitation of this study is the inaccurate presentation of response and remission rates in the studies, requiring the estimation of approximate numbers of responders and remitters in the trials. However, sensitivity analysis showed that this approximation did not influence the results. Another limitation is that we extracted the number of patients with remission in one study by means of WebPlotDigitizer; although it has already been used in other medical studies, its accuracy has not yet been tested systematically. The strength of our report is the use of multiple sensitivity analyses, which allowed us to estimate the efficacy of desvenlafaxine in a relatively homogeneous population, while no information was lost since all trials were considered in at least one estimate of effect size.
Conclusions
In our meta-analysis the efficacy of desvenlafaxine was found to be moderate when compared to placebo. Direct comparisons to other antidepressants provide some evidence that desvenlafaxine might not be as efficient as other agents; however, these comparisons included only a small number of trials. Further head-to-head trials are necessary in order to draw definite conclusions. Based on the current literature we cannot support the view that desvenlafaxine should be used as a standard antidepressant agent; more evidence on its efficacy needs to be provided.
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